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Abstract
Imaging studies play an important role in the diagnosis
and management of patients with pancreatic adenocar-
cinoma. Computed tomography (CT) is the most widely
available and best validated modality for imaging these
patients. Meticulous technique following a well-designed
pancreas protocol is essential for maximizing the diag-
nostic efﬁcacy of CT. After the diagnosis of pancreatic
adenocarcinoma is made, the key to management is
staging to determine resectability. In practice, staging
often entails predicting the presence or absence of vas-
cular invasion by tumor, for which several radiologic
grading systems exist. With advances in surgical tech-
niques, the deﬁnition of resectability is in evolution, and
it is crucial that radiologists have an understanding of
the implications of ﬁndings that are relevant to the
determination of resectability.
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Pancreatic adenocarcinoma is the second most common
gastrointestinal malignancy and the fourth leading cause
of cancer deaths in the United States. Imaging studies
have an important role in the diagnosis and management
of patients with pancreatic adenocarcinoma. Early tumor
detection and accurate radiological staging are crucial
for identifying patients with potentially resectable dis-
ease, and avoiding unnecessary surgery in patients with
unresectable disease. Computed tomography (CT) is the
imaging modality of choice in this setting because it is
widely available and the best validated tool for the
diagnosis and staging of pancreatic adenocarcinoma [1].
In this article, we review the technical aspects of a pan-
creas protocol CT and the findings relevant to diagnosis
and staging of pancreatic adenocarcinoma.
The pancreas protocol CT
The goals of a CT protocol for imaging of patients with
pancreatic adenocarcinoma are to (1) maximize the
attenuation difference between tumor and normal pan-
creas to increase the conspicuity of the lesion, (2) ade-
quately opacify peripancreatic arteries and veins to
facilitate evaluation for vascular involvement by tumor,
and (3) optimize enhancement of the liver to aid in
detection of hepatic metastases. Although the details of a
‘‘pancreas protocol’’ vary from institution to institution,
several basic principles should always be observed.
The pancreas is supplied by splanchnic arteries,
whereas the liver is largely supplied by the portal vein.
Therefore, peak enhancement of the pancreas occurs
after peak enhancement of the aorta (which occurs dur-
ing the arterial phase), but before peak enhancement of
the liver (which occurs during the portal venous phase).
Lu et al. described the pancreatic phase as an interme-
diate between the arterial phase and venous phase, dur-
ing which there is maximal enhancement of the pancreas,
resulting in maximal contrast between tumor and pan-
creatic parenchyma. At the same time, there is sufﬁcient
enhancement of peripancreatic arteries and veins to as-
sess for vascular involvement by tumor [2, 3]. Thus,
images obtained in the pancreatic phase are ideal for
both detection and local staging of pancreatic adeno-
carcinoma.
To maximize the attenuation difference between
hypovascular metastases and hepatic parenchyma, ima-
ges are then obtained in the portal venous phase, when
there is peak hepatic enhancement [4].
Early studies using multiphase CT for imaging of
patients with pancreatic adenocarcinoma often made use
of arterial phase images. Recent studies found that
images obtained in the arterial phase are unnecessary, as
they are inferior to those obtained in the pancreatic
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Thus, a pancreas protocol CT should be a dual-phase
exam with images obtained during the pancreatic phase
and hepatic phase. Noncontrast images that are useful
for detecting calciﬁcations and conﬁrming that
enhancement is present on postcontrast images may also
be obtained.
Zamboni et al. reported that there is no difference in
the diagnostic efﬁcacy of different generations of helical
CT scanners (i.e., 4-, 8-, 16-, and 64-row scanners) [7].
Using the volumetric data acquired with modern CT
scanners, a variety of postprocessing (including multi-
planar reformation, maximum intensity projection,
minimum intensity projection, volume rendering, and
curved planar reformation) are possible, and may be
performed at the discretion of the radiologist. Ichikawa
et al. reported that coronal and sagittal images improve
the performance of CT for evaluating patients with
pancreatic cancer, especially when assessing for local
extension [5]. The utility of other postprocessing tech-
niques for routine imaging of patients with pancreatic
adenocarcinoma has yet to be established.
The pancreas protocol used at our institution is given
in Table 1. Patients fast for at least 4 h before the exam
and are given 500 mL of water orally as negative contrast
agent just before the scan. About 40–45 g of iodine (e.g.,
125 cc of a contrast agent containing 350 mg of iodine
per mL) is administered intravenously to ensure ade-
quate enhancement. Contrast is power-injected at a rate
of 3 cc/s. We prefer this relatively low injection rate be-
cause it results in longer imaging windows, thus reducing
the possibility of timing errors.
A variety of methods for timing of image acquisition
can be used. The simplest, but least reliable, is a ﬁxed
delay. With the contrast volume and injection rate de-
scribed above, we acquire pancreatic phase images 40–
45 s after beginning of contrast injection on a 1- or 4-
detector scanner and 50–55 s after beginning of contrast
injection on a 16- or 64-detector scanner. Note that the
faster the scanner, the shorter the acquisition time, and
therefore the longer the delay before image acquisition.
The use of a ﬁxed delay is not recommended with 16- or
64-detector scanners because the pancreas is imaged over
only a few seconds and accurate timing becomes critical.
Using bolus tracking technique, timing of image
acquisition is tailored to the patient’s cardiac output.
Attenuation of the aorta at the level of the celiac artery is
monitored with continuous low-dose scans. When the
attenuation of the aorta reaches a deﬁned threshold (we
use 150 HU), image acquisition is triggered after a ﬁxed
delay, the length of which depends on scanner speed. On
a 64-detector scanner, we use a 30-s delay for pancreatic
phase images. Hepatic phase images are obtained 10 s
after completion of the acquisition of pancreatic phase
images.
In our protocol, unenhanced images are recon-
structed at 5 mm thickness in the axial plane, pancreatic
phase images are reconstructed at 2 mm thickness in the
axial, coronal, and sagittal planes, and portal venous
phase images are reconstructed at 5 mm thickness in the
axial plane. One mm images are sent to a 3D-capable
workstation, where a variety of postprocessing can be
performed.
With volumetric acquisition and the capability to
perform 3D postprocessing, our pancreas protocol CT is
essentially a CT angiogram (CTA). An important dif-
ference is that unlike a traditional CTA, our pancreatic
CTA images are acquired in the pancreatic phase, which
simultaneously captures both the arterial and venous
systems. We routinely obtain multiplanar reformations
of pancreatic phase images in coronal and sagittal planes,
but additional postprocessing is largely reserved for
speciﬁc problem-solving situations.
Diagnosis of pancreatic
adenocarcinoma by CT
CT has a high sensitivity for detecting pancreatic ade-
nocarcinoma, ranging from 89% to 97% [8]. As expected,
CT has a higher sensitivity for larger lesions than smaller
ones. Legmann et al. reported that CT detected 100% of
tumors >15 mm in size, but only 67% of tumors
£15 mm in size [9]. Similarly, a recent study by Bronstein
et al. found that CT detected only 77% of pancreatic
tumors £2 cm in size [10].
Table 1. Pancreatic multidetector row computed tomography (MDCT)
protocol at UCLA
MDCT generation 16 row 64 row
Contrast 125 mL of 350 mg I/mL
contrast agent
infused at 3 cc/s
Scan timing
Pancreatic phase (PP)
Fixed delay 50 s 55 s
Bolus tracking 150 HU trigger
+2 5s
150 HU trigger
+3 0s
Hepatic phase (HP)
Fixed delay 70 s 75 s
Bolus tracking End of PP + 10 s End of PP + 10 s
Scan volume Diaphragm to
iliac crests
Diaphragm to
iliac crests
Scan direction Cranial to caudal Cranial to caudal
Collimation (mm) PP: 0.75, HP: 1.5 PP: 0.6, HP: 1.5
Table feed/rotation (mm) PP: 12, HP: 24 PP: 38, HP: 76
Rotation time (s) 0.5 0.5
KVp 120 120
MAs 200–250 200–250
Image reconstruction
Routine
(thickness/interval)
(mm)
PP axial: 2/2 PP axial: 2/2
PP coronal: 2/1 PP coronal: 2/1
PP sagittal: 2/2 PP sagittal: 2/2
HP axial: 5/2.5 HP axial: 5/2.5
Optional
(thickness/interval)
(mm)
PP axial: 1/1 PP axial: 1/1
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deﬁned hypoattenuating masses, but can be isoattenu-
ating to the surrounding parenchyma. Prokesch et al.
reported that 11% of pancreatic cancers are isoattenu-
ating on both pancreatic phase and hepatic phase images.
In most cases, the presence and location of a pancreatic
mass could still be inferred from secondary signs, such as
interruption and dilation of the pancreatic duct and/or
the common bile duct, mass effect, convex abnormality
of the contour of the pancreas, and atrophy of the
pancreas [11] (Fig. 1).
Although radiologic signs used to diagnose pancreatic
adenocarcinoma are not pathognomonic of the condi-
tion, biopsy is usually unnecessary before surgical inter-
vention in patients with potentially resectable disease. If
there are confounding factors (such as clinical ﬁndings
that suggest pancreatitis), biopsy may be performed
endoscopically, percutaneously, or surgically. If the pa-
tient is not a surgical candidate, conﬁrmation of the
diagnosis by biopsy is usually necessary prior to che-
motherapy and/or radiation therapy.
Ideally, CT should be performed before biliary
stenting, as the stent may cause artifact in the pancreatic
head that can mask the lesion, and the trauma of stent
insertion often produces inﬂammatory changes that can
be indistinguishable from tumor.
Staging and resectability
Complete surgical resection is the only potentially cura-
tive treatment for pancreatic adenocarcinoma, but only
15–20% of patients present with resectable disease. Sur-
vival rate after resection is about 12–20% at 5 years,
compared to <1% for those with unresectable disease. In
many patients, the only obstacle to resection is involve-
ment of the portal vein or superior mesenteric vein,
which was once considered an absolute contraindication
to pancreaticoduodenectomy. However, venous resection
and reconstruction are now commonly performed, with
morbidity, mortality, and survival similar to pancreati-
coduodenectomy without vascular reconstruction [12].
Reﬂecting this development, the American Joint
Commission on Cancer (AJCC) TNM staging system for
pancreatic adenocarcinoma was revised in the 6th edition
of the AJCC Cancer Staging Manual (Table 2). Isolated
venous involvement is now considered T3 disease (locally
invasive, but potentially resectable), whereas tumor
involvement of the celiac artery or superior mesenteric
artery remains T4 disease (locally advanced and unre-
sectable) [13, 14]. Arterial resection and reconstruction is
technically difficult, and complete tumor resection is
rarely possible due to tumor infiltration along the nerves
of the celiac plexus.
Current criteria for resectability include absence of
distant metastases, lack of evidence of tumor involve-
ment of major arteries, and (if there is venous invasion) a
suitable segment of portal vein (above) and superior
mesenteric vein (below) the site of venous involvement to
allow for venous reconstruction [15]. Precisely what is
considered resectable venous involvement depends on the
preferences of the treating surgeon, but ideally the re-
sected segment of vein should be downstream (i.e., closer
to the liver) from the entry of the jejunal veins, and the
involved segment of portal or superior mesenteric vein
should be <2 cm in length [12].
Because there are no universally accepted criteria for
determining resectability, the terms ‘‘resectable’’ and
‘‘unresectable’’ should be used only when there is a clear
understanding between the radiologist and the referring
physician. In radiologic reports, ﬁndings relevant to the
staging of pancreatic adenocarcinoma are often de-
scribed, without speciﬁcally stating whether or not a
patient has resectable disease.
Fig. 1. Sixty-nine-year-old male with an isodense pancreatic
head mass. A Coronal CT image demonstrates marked biliary
ductal dilation, with abrupt narrowing of the common bile duct
in the pancreatic head (arrow), where no mass is identified. B
Endoscopic retrograde cholangiopancreaticography demon-
strates similar findings. Endoscopic ultrasound performed at
the same time revealed a 3 9 2 cm mass in the head of the
pancreas that was biopsied and found to be an adenocarci-
noma.
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Although patients with T1 disease have a better prog-
nosis than patients with T2 disease [16], differentiation
between the two groups has little impact on management
since both have potentially resectable disease. On the
other hand, distinguishing patients with T3 disease from
those with T1 or T2 disease and distinguishing patients
with T4 disease from those with T3 disease are of para-
mount importance. Patients with T3 disease may or may
not have resectable disease depending on the skills and
preferences of the treating surgeon, while patients with
T4 disease have unresectable disease. Thus, the key to T
staging of pancreatic adenocarcinoma is identification of
vascular invasion by tumor.
The most commonly used system for predicting vas-
cular invasion by pancreatic adenocarcinoma is a ﬁve-
grade scale proposed by Lu et al. based on the degree of
contact between tumor and a vessel (Table 3). Tumor
contiguity with >50% of the perimeter of a vessel was
found to be the optimal threshold for predicting vascular
invasion, with a sensitivity of 84% and specificity of 98%
[17] (Figs. 2, 3).
An important, but often overlooked, component of
the grading scale proposed by Lu et al. is vessel defor-
mity, which is considered a sign of vascular invasion
regardless of the degree of contact between the vessel and
tumor. Illustrating the importance of this, Hough et al.
described the teardrop superior mesenteric vein sign as a
speciﬁc sign of unresectable pancreatic adenocarcinoma.
The teardrop sign is present when the normal round
shape of the vessel is changed to a teardrop shape on
axial images [18]. Because venous resection was not an
option at the authors’ institution at the time of the study,
the teardrop sign should be considered a sign of superior
mesenteric venous invasion by tumor rather than unre-
sectability.
Modiﬁcations to the grading system proposed by Lu
et al. have been proposed to increase sensitivity for
detecting venous invasion and speciﬁcity for detecting
arterial invasion [19–21] (Table 4). Higher sensitivity for
predicting venous invasion is desirable because patients
with undiagnosed venous invasion may be deemed to
have ‘‘unresectable’’ disease at surgery if resection is at-
tempted at an institution where venous reconstruction is
not performed. On the other hand, higher specificity for
predicting arterial invasion reduces the risk of overstag-
ing patients with T3 disease and denying them the chance
for surgical resection. Additional studies are needed to
confirm the validity of these recommendations.
Other systems for predicting vascular invasion by
pancreatic adenocarcinoma have been proposed. Al-
Table 2. The 6th edition of the American Joint Commission on cancer staging system for pancreatic adenocarcinoma [14]
Definition Comments
Primary tumor (T)
T0 No evidence of primary
Tis In situ
T1 Limited to pancreas, £2c m
T2 Limited to pancreas, >2c m
T3 Extends beyond the pancreas, but
without involvement of the ce-
liac artery or superior mesenteric
artery
Emphasis is on factors that determine
resectability. In the 6th edition, only
extrapancreatic extension to the celiac
artery or superior mesenteric artery is
T4. In the 5th edition, extrapancreatic
extension to the stomach, spleen, colon,
portal vein, and superior mesenteric
vein was also considered T4.
T4 Involves the celiac artery or supe-
rior mesenteric artery
Regional lymph nodes (N)
N0 No nodal metastases In the 6th edition, no distinction is made
between the number of nodes involved.
In the 5th edition, N1 was subdivided
into N1a (involvement of a single node)
and N1b (involvement of more than
one node)
N1 Regional nodal metastases
Distant metastases (M)
M0 No distant metastases
M1 Distant metastases
Stage groupings
Stage 0 Tis N0 M0
Stage I IA: T1 N0 M0 Potentially resectable.
IB: T2 N0 M0
Stage II IIA: T3 N0 M0 Potentially resectable.
IIB: T1–3 N1 M0
Stage III T4 N0-1 M0 Locally advanced and unresectable.
Stage IV T1–4 N0-1 M1 Metastatic and unresectable.
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with them, as they are occasionally encountered in the
literature (Tables 5, 6). Loyer et al. found that a tumor
that abuts a vessel usually does not invade it if the points
of contact form a convexity against the vessel (i.e., the
mass displaces or compresses, but does not wrap around,
the vessel). On the other hand, if the points of contact
form a concavity against the vessel (i.e., the mass wraps
around the vessel), vascular invasion is often present [22].
Raptopoulos et al. found that a vessel that is encased and
narrowed by tumor is likely to be invaded by it [23].
Encasement was originally defined by the authors as
tumor extending around least two-thirds of the perimeter
of a vessel, but in a recent article published by the same
group, encasement was defined as extension of tumor
around at least 50% of the perimeter of a vessel [24].
It is important to note any variant vascular anatomy
that may be present. Anatomic variants may render
resectable a tumor that would otherwise be unresectable
(e.g., a celiac artery that does not give rise to the com-
mon hepatic artery may be sacriﬁced) or render unre-
sectable a tumor that would otherwise be unresectable
(e.g., isolated involvement of a replaced right hepatic
artery by tumor) (Fig. 4).
TNM staging: regional lymph
nodes (N)
The accuracy of CT for predicting nodal metastases is
low. Lymph nodes that are normal in size may harbor
micrometastases, whereas enlarged lymph nodes are often
reactive. Roche et al. reported that CT diagnosedregional
nodal metastases in patients with pancreatic adenocarci-
noma with a sensitivity of 14% and a speciﬁcity of 85% if
a short-axis diameter of 10 mm is used as the sole crite-
rion for tumor involvement. Using a short-axis diameter
of 5 mm as threshold increased sensitivity to 71%, but
reduced speciﬁcity to 64%. Morphologic features (roun-
ded nodes, clustered nodes, nodes with no fatty hilum)
were not found to be helpful. The authors concluded that
in a patient with pancreatic adenocarcinoma, the ﬁnding
of enlarged peripancreatic lymph nodes on CT should not
preclude attempted resection [25].
In practice, peripancreatic lymph nodes are resected
en bloc with the primary tumor, and preoperative
detection of peritumoral lymphadenopathy is not essen-
tial for assessing the resectability of pancreatic adeno-
Table 3. Grading system proposed by Lu et al. [17] for predicting vascular invasion by tumor based on the degree of tumor contiguity with a vessel
Category Description Comment
Grade 0 No contiguity of tumor with a vessel Vascular invasion in 0% of cases
Grade 1 Tumor contiguous with <25% of the circumference of a vessel Vascular invasion in 0% of cases
Grade 2 Tumor contiguous with 25–50% of the circumference of a vessel Vascular invasion in 57% of cases
Grade 3 Tumor contiguous with 50–75% of the circumference of a vessel Vascular invasion in 88% of cases
Grade 4 Tumor contiguous with >75% of the circumference of a vessel or any vessel constriction Vascular invasion in all cases
Fig. 2. Eighty-two-year-old female with resectable pancre-
atic adenocarcinoma. Axial CT image demonstrates a hypo-
vascular mass in the head of the pancreas (large arrow). The
tumor abuts the posterior aspect of the superior mesentery
artery (small arrow), but the area of contact encompasses
only 25% of the circumference of the vessel and there is no
deformity of the vessel. The patient underwent successful
pancreaticoduodenectomy and was well at the time of this
article was written, 11 months after surgery.
Fig. 3. Fifty-four-year-old female with locally advanced
pancreatic adenocarcinoma. Axial CT image demonstrates a
hypovascular mass in the head of the pancreas (large arrow)
that encircles both the superior mesenteric vein (arrowhead)
and superior mesenteric artery (small arrow). There is
deformity of the superior mesenteric vein, which is an indi-
cation of vascular invasion, regardless of the degree of con-
tact between the vessel and tumor.
J. C. Wong and S. Raman: Surgical resectability of pancreatic carcinoma: CTA 475carcinomas. Illustrating this, DeWitt et al. reported that
72% of resectable tumors had regional nodal involve-
ment, compared to only 50% of unresectable pancreatic
tumors [26].
TNM staging: distant metastases (M)
Because distant metastases (M1 disease) contraindicates
tumor resection, their detection is an important part of
Table 4. Sensitivity and specificity for predicting vascular invasion by tumor using 50% tumor contiguity with the circumference of a vessel as
threshold
Authors Sensitivity (%) Specificity (%) Comment/Proposed modification(s)
Lu et al. [17] 84 98 In this study, vessel constriction was considered a
sign of vascular invasion, regardless of the degree
of contact between vessel and tumor. Tumor
contiguity with 50% of the circumference of a
vessel was used as a criterion only in cases without
vessel constriction.
O’Malley et al. [19] 46 99 In this study, the grading system proposed by Lu
et al. was modified to exclude vessel constriction
as a sign of vascular invasion. This may account
for the lower sensitivity reported. Raising the
threshold to 75% decreased sensitivity to 38%, but
increased specificity to 100%.
Nakayama et al. [20]—veins only 71 86 The criteria used by Lu et al. were found to be
optimal.
Nakayama et al. [20]—arteries only 78 79 Raising the threshold to 75% decreased sensitivity to
61%, but increased specificity to 92%.
Li et al. [21]—veins only 49 100 Including venous obliteration, venous stenosis, or
teardrop SMV as signs of venous invasion in-
creased sensitivity to 92% while specificity re-
mained 100%. Note that these criteria are identical
to those proposed by Lu et al.
Li et al. [21]—arteries only 97 91 Using a combination of tumor involvement of >50%
of the circumference of an artery and irregularity
of the arterial wall or stenosis of the artery reduced
sensitivity to 79%, but increased specificity to 99%.
Table 5. Grading system proposed by Loyer et al. [22] for predicting vascular invasion by tumor
Category Description Comment
Type A Fat plane separates the tumor and/or the normal
pancreatic parenchyma from adjacent vessels
Overall resection rate: 100%. Resection rate without
venous resection: 95%. Conclusion: ‘‘Lesions with
type A and B appearances are likely to be resect-
able lesions’’
Type B Normal parenchyma separates the hypodense tumor
from adjacent vessels
Overall resection rate: 100%. Resection rate without
venous resection: 95%. Conclusion: ‘‘Lesions with
type A and B appearances are likely to be resect-
able lesions’’
Type C Hypodense tumor is inseparable from adjacent ves-
sels, and the points of contact form a convexity
against the vessels
Overall resection rate: 89%. Resection rate without
venous resection: 55%. Conclusion: ‘‘Lesions of
type C vascular involvement should be operated
on with an intention to resect the tumor, but the
tumor may or may not adhere to the wall of the
vessels’’
Type D Hypodense tumor is inseparable from adjacent ves-
sels, and the points of contact form a concavity
against the vessels or partially encircle the vessels
Overall resection rate: 47%. Resection rate without
venous resection: 7%. Conclusion: ‘‘Lesions of
type D vascular involvement would require pan-
creatic resection with a plan to perform venous
resection and venous graft or patch or would be
unresectable for surgeons who do not have that
appearance’’
Type E Hypodense tumor encircles adjacent vessels, and no
fat plane is identified between the tumor and the
vessels
Overall resection rate: 0%. Resection rate without
venous resection: 0%. Conclusion: ‘‘Lesions of the
type E and F vascular involvement are not likely
to be resectable’’
Type F Tumor occludes the vessels Overall resection rate: 0%. Resection rate without
venous resection: 0%. Conclusion: ‘‘Lesions of the
type E and F vascular involvement are not likely
to be resectable’’
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peritoneal surfaces are common sites for distant metas-
tases.
Hepatic metastases from pancreatic adenocarcinoma
appear as solid hypovascular masses with imaging fea-
tures similar to the primary tumor (Fig. 5). When a le-
sion is large, the diagnosis of metastatic disease to the
liver is usually straightforward. If imaging findings are
equivocal, a large lesion can be biopsied percutaneously.
A commonly encountered problem when staging
cancer patients with CT is the presence of small
(£10 mm) hypodense lesions that are often described by
radiologists as ‘‘too small to characterize’’ or ‘‘indeter-
minate.’’ Because of partial volume averaging and/or
pseudo-enhancement, the attenuation of these lesions
cannot be accurately measured [27]. Although usually
benign, Schwartz et al. found that such lesions represent
metastases in 11.6% of patients with cancer [28]. Follow-
up imaging of these lesions is an option, but there are no
established guidelines defining the frequency and dura-
tion of follow-up imaging. Furthermore, delaying sur-
gery in patients who are otherwise surgical candidates is
impractical. Percutaneous biopsy may yield a definitive
diagnosis, but is often technically difficult. In practice,
resection is often attempted despite the presence of these
lesions. Unexpected hepatic metastases are responsible
Table 6. Grading system proposed by Raptopoulos et al. [23] for predicting vascular invasion by tumor
Category Description Comment
Grade 0 Normal, with a fat plane or normal pancreas be-
tween the tumor and the vessel
100% resectable
Grade 1 Loss of fat plane between the tumor and the vessel,
with or without smooth displacement of the vessel
100% resectable
Grade 2 Flattening or slight irregularity of one side of the
vessel
92% resectable
Grade 3 Encased vessel with tumor extending around at least
two sides (two-thirds of the perimeter), altering its
contour and producing concentric or eccentric
narrowing of the lumen
a
The recommended threshold for predicting vascular
invasion. In this study, resection was performed in
1 of 10 patients with grade 3 findings, but tumor
along perivascular neural bundles was present at
resection margins.
Grade 4 Occluded vessel No attempted surgery
aIn a recent article by the same group, encasement was defined as tumor extending around 50% of the perimeter of a vessel [24]
Fig. 4. Forty-three-year-old male with locally advanced
pancreatic adenocarcinoma. (A–E) Sequential coronal CT
images demonstrate a replaced right hepatic artery (small
arrow) arising from the superior mesenteric artery. The
aberrant vessel is mildly deformed by a hypovascular mass in
the pancreatic head (large arrow), suggesting tumor invasion
of the vessel. This was not prospectively identified, and the
patient was found at surgery to have unresectable disease
due to invasion of a replaced right hepatic artery.
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lesions account for many of these cases, but some hepatic
metastases are not apparent on CT even in retrospect [8,
29, 30].
Peritoneal carcinomatosis is common in patients with
advanced pancreatic adenocarcinoma. CT ﬁndings of
peritoneal carcinomatosis include ascites, peritoneal
thickening and contrast enhancement, nodular bowel
wall thickening representing serosal implants, and soft
tissue inﬁltration of the omentum [31] (Fig. 6). Peritoneal
carcinomatosis is easily diagnosed by CT when ad-
vanced, but the sensitivity of imaging studies for small
peritoneal implants is limited. Diehl et al. reported that
CT identified only 80% of patients found to have peri-
toneal metastases at surgery [25].
Performance of CT for staging
pancreatic adenocarcinoma
Because of the dismal prognosis of patients who do not
undergo complete tumor resection, the criteria used to
predict vascular invasion by tumor are biased toward
high speciﬁcity, at the cost of sensitivity, to avoid deny-
ing surgery to patients with potentially resectable disease.
Furthermore, the sensitivity of CT for small hepatic and
peritoneal metastases is limited. It is, therefore, not sur-
prising that although the positive predictive value of CT
for predicting unresectability is high (89–100%), its po-
sitive predictive value for predicting resectability is much
lower (45–79%)[ 24]. When interpreting these statistics, it
should be remembered that the definition of resectability
is evolving, and what was once considered unresectable
disease may now be resectable.
Restaging of pancreatic
adenocarcinoma after neoadjuvant
chemoradiation therapy
Neoadjuvant, or preoperative, chemoradiation therapy is
used to downstage patients with locally advanced disease
or to improve survival in patients who present with
resectable tumors. Restaging after neoadjuvant therapy
is an important part of the management of these patients,
but local inﬂammatory changes induced by neoadjuvant
therapy may confound assessment for vascular involve-
ment by tumor.
White et al. reported that among patients who re-
ceived preoperative therapy, 22% with locally advanced
disease diagnosed by CT were found to be resectable at
surgery. Some of them had positive surgical margins, but
at a rate no higher than patients deemed to have
potentially resectable disease by CT. The authors rec-
ommended that only venous occlusion be considered
unequivocal evidence of locally advanced disease, and all
other ﬁndings that may represent vascular invasion
should be conﬁrmed by endoscopic ultrasound and ﬁne
needle aspiration [32]. Tamm et al. reported that of four
patients with questionable vascular involvement by tu-
mor after neoadjuvant therapy, only one was found to be
unresectable at the time of surgery [33].
In a more recent study, Kim et al. reported the po-
sitive predictive value of CT for resectability among
patients who received neoadjuvant therapy to be 91%.
The authors concluded that neoadjuvant therapy does
not signiﬁcantly affect the determination of tumor
resectability by CT. A major drawback of the study is
that all except one of the patients studied had resectable
disease. CT failed to predict the unresectability of the
only patient who was unsuccessfully resected (resulting in
a speciﬁcity of 0% for resectability), and the only patient
Fig. 5. Seventy-year-old male with metastatic pancreatic
adenocarcinoma. A Axial CT image demonstrates a hypo-
vascular mass in the pancreatic head (large arrow) and an
enlarged peripancreatic lymph node (small arrow). B Axial CT
image demonstrates multiple hypovascular lesions in the liver
(small arrows), with imaging features similar to the primary
tumor in the pancreas.
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successfully resected (resulting in a negative predictive
value for resectability of 0%)[ 34].
It is likely that modiﬁcation of the current criteria for
predicting unresectability of pancreatic adenocarcinoma
will be needed for the evaluation of patients who received
neoadjuvant therapy. For example, Kim et al. did not
consider the presence of a perivascular halo (deﬁned as a
thin, low-attenuation lesion surrounding a vessel) to be a
sign of vascular invasion. The authors speculated that
this may be one of the reasons for the high positive
predictive value for resectability achieved in the study
[34]. Further research on this topic is needed.
Conclusion
Diagnostic imaging plays a vital role in the management
of patients with pancreatic adenocarcinoma, and CT is
currently the modality of choice. To maximize the diag-
nostic efﬁcacy of CT, meticulous technique following a
well-designed pancreas protocol is essential. Once the
diagnosis of pancreatic adenocarcinoma is made, the key
to management is determining resectability. Despite ad-
vances in nonoperative management of pancreatic ade-
nocarcinoma, complete surgical resection remains the
only potentially curative therapy. With development of
new surgical techniques, the deﬁnition of resectability is
in evolution. Patients with tumors that were once con-
sidered to be unresectable may now be surgical candi-
dates at some centers. It is, therefore, important
that radiologists describe in detail the ﬁndings that are
relevant for staging of pancreatic adenocarcinoma and
have a clear understanding of the implications of these
ﬁndings.
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